Pre-Seed fundraising round
TrueYouOmics (TYO) upcoming Pre-Seed round marks a pivotal moment in our trajectory, enabling us to bring our commercial MVP to life and launch in our first market. We seek partners in the US and Europe with proven expertise in BioTech, Consumer Health, and Life Science and investors who share our vision of transforming healthcare through early disease risk detection and prevention.
Book a meeting with us
Dominic Mehr (Co-founder and CCO, TYO) at the START Summit conference.
Funding goal
We aim to raise CHF 2 M to finance our next 12-18 months of operations. The funds will power three critical milestones:
1. Pilot validation: Run our pilot with blood samples collected from volunteers in collaboration with a leading university hospital. This effort focuses on validating our disease risk assessment model while ensuring the technical robustness of our approach.
2. Early Access Program: Prepare and deploy our commercial Minimal Viable Product (MVP) with at least 50 paying consumers, capturing real-world feedback to prepare the commercial launch.
3. Official Market Launch: Finalize and launch our commercial product, securing our position as a leader in early disease risk detection for consumers.
Use of funds
To achieve the above milestones , we plan to:
1. Build the core team: Strengthen our expert lineup, supporting the founders across key domains (AI, business development, regulatory, legal, etc).
2. Pilot and partnership costs: Cover lab fees, consumables, and partnership expenses with our partner university hospital.
3. User acquisition: Drive initial awareness and adoption for both our Early Access Program and Official Market Launch.
4. Licensing model financing: Secure the first 500 blood samples needed to initiate collaborations with pharma and other businesses.
5. OPEX & setup costs: Sustain operational and administrative expenses as we scale.
Photo by Kaboompics on Pexels.
Timeline 2025
Join us in revolutionizing preventive healthcare by empowering individuals with actionable insights. Together, we can shape a future where early disease risk detection and prevention is the new standard of care.
Book a meeting with us
